Viral inhibition assay: A CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 720-729

  Spentzou, Aggeliki ^a   Bergin, Philip ^a   Gill, Dilbinder ^a   Cheeseman, Hannah ^a   Ashraf, Ambreen ^a   Kaltsidis, Harry ^a   Cashin Cox, Michelle ^a   Anjarwalla, Insiyah ^a   Steel, Alan ^b   Higgs, Christopher ^b   Pozniak, Anton ^b   Piechocka Trocha, Alicja ^c   Wong, Johnson ^d   Anzala, Omu ^f   Karita, Etienne ^g   Dally, Len ^e   Gotch, Frances ^a   Walker, Bruce ^c   Gilmour, Jill ^a   Hayes, Peter ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e EMMES CORPORATION   (United States)

^f UNIVERSITY OF NAIROBI   (Kenya)

^g Projet San Francisco   (Rwanda)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIRETROVIRUS AGENT; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AGED; ARTICLE; ASSAY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPRODUCIBILITY; VIREMIA; VIRUS INHIBITION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; ADULT; AGED; AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRUS REPLICATION;

EID: 76449116461     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650492     Document Type: Article

References (41)

1. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-4789.
2. Borrow P, Lewicki H, Hahn BH, Shaw GM, OldstoneMB.Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-6110.
3. Friedrich TC, Valentine LE, Yant LJ, et al. Subdominant CD8+ T cell responses are involved in durable control of AIDS virus replication. J Virol 2007; 81:3465-3476.
4. Goulder PJ, Phillips RE, Colbert RA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-217.
5. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996; 156:2616-2623.
6. Heintel T, Sester M, Rodriguez MM, et al. The fraction of perforinexpressing HIV-specific CD8 T cells is a marker for disease progression in HIV infection. AIDS 2002; 16:1497-1501.
7. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV- 1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-1372.
8. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
9. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
10. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-1180
11. Rinaldo C, Huang XL, Fan ZF, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV- 1-infected long-term nonprogressors. J Virol 1995; 69:5838-5842.
12. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-1893.
13. Darrah PA, Patel DT, De Luca PM, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850.
14. Boaz MJ, Hayes P, Tarragona T, et al. Concordant proficiency in measurement of T cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzymelinked immunospot assays in laboratories from three continents. Clin Vaccine Immunol 2009; 16:147-155.
15. Valentine LE, Piaskowski SM, Rakasz EG, Henry NL,Wilson NA,Watkins DI. Recognition of escape variants in ELISPOT does not always predict CD8+ T cell recognition of simian immunodeficiency virusinfected cells expressing the same variant sequences. J Virol 2008; 82: 575-581.
16. Gray CM, Mlotshwa M, Riou C, et al. Human immunodeficiency virusspecific gamma interferon enzyme-linked immunospot assay responses targeting specific regions of the proteome during primary subtype C infection are poor predictors of the course of viremia and set point. J Virol 2009; 83:470-478.
17. Lieberman J. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS 2004; 18:1489-1493.
18. Yang OO. Will we be able to 'spot' an effective HIV-1 vaccine? Trends Immunol 2003; 24:67-72.
19. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
20. Bennett MS, Ng HL, Ali A, Yang OO. Cross-clade detection of HIV- 1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J Infect Dis 2008; 197:390-397.
21. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO. Epitope-dependentavidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 2007; 81:4973-4980.
22. Fauce SR, Yang OO, Effros RB. Autologous CD4/CD8 co-culture assay: a physiologically-relevant composite measure of CD8+ T lymphocyte function in HIV-infected persons. J Immunol Methods 2007; 327: 75-81.
23. Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-1660.
24. Catanzaro AT, Koup RA, Roederer M. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649.
25. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T- 20) monotherapy. Antimicrob Agents Chemother 2002; 46:1896-1905.
26. Jones N, Agrawal D, Elrefaei M, et al. Evaluation of antigen-specific responses using in vitro enriched T cells. J Immunol Methods 2003; 274:139-147.
27. Wong JT, Colvin RB. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. J Immunol 1987; 139:1369-1374.
28. Peters BS, Jaoko W, Vardas E, et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 2007; 25:2120-2127.
29. Watkins DI. The hope for an HIV vaccine based on induction of CD8+ T lymphocytes: a review. Mem Inst Oswaldo Cruz 2008; 103:119-129.
30. Barker TD, Weissman D, Daucher JA, Roche KM, Fauci AS. Identification of multiple and distinct CD8+ T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to gamma irradiation. J Immunol 1996; 156:4476-4483.
31. Hsueh FW, Walker CM, Blackbourn DJ, Levy JA. Suppression of HIV replication by CD8+ cell clones derived from HIV-infected and uninfected individuals. Cell Immunol 1994; 159:271-279.
32. Le Borgne S, Fevrier M, Callebaut C, Lee SP, Riviere Y. CD8+-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription. J Virol 2000; 74:4456-4464.
33. Migueles SA, Weeks KA, Nou E, et al. Defective HIV-specific CD8+ T cell polyfunctionality, proliferation and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009; 83(22):11876-11889.
34. Yang OO, Sarkis PT, Ali A, et al. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med 2003; 197:1365-1375.
35. Chen H, Piechocka-Trocha A, Miura T, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol 2009; 83: 3138-3149.
36. Goulder PJ, Altfeld MA, Rosenberg ES, et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001; 193:181-194.
37. Lichterfeld M, Yu XG, Cohen D, et al. HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS 2004; 18:1383-1392.
38. Letourneau S, Im EJ, Mashishi T, et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007; 2:e984.
39. Yang OO. CTL ontogeny and viral escape: implications for HIV-1 vaccine design. Trends Immunol 2004; 25:138-142.
40. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008; 29:1009-1021.
41. D'Souza MP, Altfeld M. Measuring HIV-1-specific T cell immunity: how valid are current assays? J Infect Dis 2008; 197:337-339.